Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GNLX |
---|---|---|
09:32 ET | 1124 | 6.07 |
09:34 ET | 100 | 5.9 |
09:38 ET | 5991 | 5.9001 |
09:39 ET | 650 | 6.2212 |
10:26 ET | 200 | 6.055 |
11:13 ET | 425 | 6.1892 |
11:54 ET | 100 | 6.11 |
12:21 ET | 200 | 6.15 |
12:34 ET | 200 | 6.1005 |
12:52 ET | 100 | 6.15 |
12:54 ET | 254 | 6.192 |
01:08 ET | 3041 | 6.155 |
01:35 ET | 100 | 6.06 |
01:39 ET | 100 | 6.0601 |
01:57 ET | 200 | 6.0975 |
02:15 ET | 200 | 6.155 |
02:20 ET | 2756 | 6.2099 |
02:22 ET | 315 | 6.1623 |
02:26 ET | 1000 | 6.2063 |
02:27 ET | 5384 | 6.225 |
02:36 ET | 200 | 6.33 |
02:38 ET | 300 | 6.3 |
03:02 ET | 100 | 6.31 |
03:03 ET | 700 | 6.31 |
03:21 ET | 601 | 6.3396 |
03:45 ET | 200 | 6.21 |
03:54 ET | 500 | 6.22 |
03:56 ET | 1395 | 6.37 |
03:57 ET | 200 | 6.38 |
03:59 ET | 31372 | 6.43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Genelux Corp | 171.8M | -5.9x | --- |
Molecular Partners AG | 147.9M | -2.0x | --- |
ProQR Therapeutics NV | 186.3M | -6.1x | --- |
Syros Pharmaceuticals Inc | 137.3M | -0.9x | --- |
Sagimet Biosciences Inc | 173.0M | -4.1x | --- |
Coya Therapeutics Inc | 144.3M | -12.1x | --- |
Genelux Corporation is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The Company is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $171.8M |
---|---|
Revenue (TTM) | $238.0K |
Shares Outstanding | 26.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.09 |
Book Value | $-1.46 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | 721.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,680.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.